M Braun
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
Loibl S, Staib P, Link T, Rhiem K, Solbach C, Fasching P, Nekljudova V, Denkert C, Untch M, Jackisch C, Thomalla J, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J, Furlanetto J, Zahm D, Hanusch C, GBG and AGO-B. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 2022
Aug 9, 2022Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
Aug 9, 2022Ann Oncol 2022
Loibl S, Staib P, Link T, Rhiem K, Solbach C, Fasching P A, Nekljudova V, Denkert C, Untch M, Jackisch C, Thomalla J, Schneeweiss A, Huober Jens, Braun M, Rey J, Blohmer J-U, Furlanetto J, Zahm D-M, Hanusch C, GBG and AGO-B
[Liver failure in a 27 years old female patient]
Gertsch T, Pfammatter T, Braun M, Hechelhammer L, Meyenberger C, Semela D, Sawatzki M. [Liver failure in a 27 years old female patient]. Praxis (Bern 1994) 2012; 101:1051-5.
Aug 8, 2012[Liver failure in a 27 years old female patient]
Aug 8, 2012Praxis (Bern 1994) 2012; 101:1051-5
Gertsch T, Pfammatter T, Braun M, Hechelhammer Lukas, Meyenberger C, Semela David, Sawatzki M